The ARGLU1 Knockout HEK293T Polyclonal Cells constitute a CRISPR/Cas9-mediated polyclonal knockout cell population designed to disrupt ARGLU1 expression. Generated from the HEK293T human embryonic kidney line, this product provides a loss-of-function model to investigate ARGLU1’s involvement in transcriptional regulation and alternative splicing. Unlike clonal lines, the polyclonal pool retains cellular heterogeneity, which can be advantageous for capturing diverse phenotypic responses.
HEK293T cells are a widely adopted host platform derived from primary human embryonic kidney cells transformed with adenovirus 5 DNA. They stably express the SV40 large T antigen, enabling high-copy episomal plasmid replication and robust transient protein expression. This property, combined with high transfection efficiency and rapid division, makes HEK293T ideal for CRISPR-based gene editing, lentivirus production, and large-scale protein manufacturing.
ARGLU1 functions as a transcriptional coactivator by directly interacting with the Mediator complex subunit MED1 to potentiate ESR1-mediated transcription. This promotes expression of key targets including PGR, TFF1, GREB1, and CCND1, linking ARGLU1 to estrogen-driven proliferative pathways. ARGLU1 also modulates alternative splicing via associations with SRSF1 and SF3B1, influencing the pro-survival BCL2L1 isoform ratio. Its expression is regulated by transcription factors MYC and TP53, and it is activated upon DNA damage by ATM/ATR kinases, integrating stress and growth signals.
Disruption of ARGLU1 in HEK293T cells impairs both ESR1-dependent transcriptional activation and apoptosis-related splicing decisions. The model is well-suited for co-transfection with ESR1 and reporter constructs to quantify ARGLU1 contribution to receptor activity using luciferase assays and ChIP-qPCR. Given the cell line’s intact splicing machinery, it also facilitates investigation of ARGLU1’s role in BCL2L1 isoform switching and other splicing targets, thereby elucidating its mechanistic impact in a controllable environment.
Researchers can leverage this knockout population for a wide array of functional studies, including transcriptomic analysis by RNA-seq, targeted gene expression profiling by RT-qPCR, and protein-level verification via western blotting and immunofluorescence. Apoptosis and proliferation assays enable phenotypic assessment, while drug response studies support target validation in cancers such as breast and prostate carcinomas. Additionally, the model is valuable for exploring ARGLU1’s contributions to neurodevelopmental disorders, including autism and intellectual disability, where its mutations have been implicated. For detailed technical consultation, contact Ascent Research.
